TY - JOUR
T1 - Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis
AU - Canet, Mark J.
AU - Hardwick, Rhiannon N.
AU - Lake, April D.
AU - Dzierlenga, Anika L.
AU - Clarke, John D.
AU - Goedken, Michael J.
AU - Cherrington, Nathan J.
N1 - Publisher Copyright:
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Nonalcoholic fatty liver disease is the most common chronic liver disease, which can progress to nonalcoholic steatohepatitis (NASH). Previous investigations demonstrated alterations in the expression and activity of hepatic drug transporters in NASH. Moreover, studies using rodent models of cholestasis suggest that compensatory changes in kidney transporter expression occur to facilitate renal excretion during states of hepatic stress; however, little information is currently known regarding extrahepatic regulation of drug transporters in NASH. The purpose of the current study was to investigate the possibility of renal drug transporter regulation in NASH across multiple experimental rodent models. Both rat and mouse NASH models were used in this investigation and include: the methionine and choline-deficient (MCD) diet, atherogenic diet, fa/fa rat, ob/ob and db/db mice. Histologic and pathologic evaluations confirmed that the MCD and atherogenic rats as well as the ob/ob and db/db mice all developed NASH. In contrast, the fa/fa rats did not develop NASH but did develop extensive renal injury compared with the other models. Renal mRNA and protein analyses of xenobiotic transporters suggest that compensatory changes occur in NASH to favor increased xenobiotic secretion. Specifically, both apical efflux and basolateral uptake transporters are induced, whereas apical uptake transporter expression is repressed. These results suggest that NASH may alter the expression and potentially function of renal drug transporters, thereby impacting drug elimination mechanisms in the kidney.
AB - Nonalcoholic fatty liver disease is the most common chronic liver disease, which can progress to nonalcoholic steatohepatitis (NASH). Previous investigations demonstrated alterations in the expression and activity of hepatic drug transporters in NASH. Moreover, studies using rodent models of cholestasis suggest that compensatory changes in kidney transporter expression occur to facilitate renal excretion during states of hepatic stress; however, little information is currently known regarding extrahepatic regulation of drug transporters in NASH. The purpose of the current study was to investigate the possibility of renal drug transporter regulation in NASH across multiple experimental rodent models. Both rat and mouse NASH models were used in this investigation and include: the methionine and choline-deficient (MCD) diet, atherogenic diet, fa/fa rat, ob/ob and db/db mice. Histologic and pathologic evaluations confirmed that the MCD and atherogenic rats as well as the ob/ob and db/db mice all developed NASH. In contrast, the fa/fa rats did not develop NASH but did develop extensive renal injury compared with the other models. Renal mRNA and protein analyses of xenobiotic transporters suggest that compensatory changes occur in NASH to favor increased xenobiotic secretion. Specifically, both apical efflux and basolateral uptake transporters are induced, whereas apical uptake transporter expression is repressed. These results suggest that NASH may alter the expression and potentially function of renal drug transporters, thereby impacting drug elimination mechanisms in the kidney.
UR - http://www.scopus.com/inward/record.url?scp=84921065324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921065324&partnerID=8YFLogxK
U2 - 10.1124/dmd.114.060574
DO - 10.1124/dmd.114.060574
M3 - Article
C2 - 25488932
AN - SCOPUS:84921065324
SN - 0090-9556
VL - 43
SP - 266
EP - 272
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 2
ER -